Overview


Vasomotor symptoms refer to temperature dysfunctions caused by changes in the gonadal hormones of females. These symptoms are caused by constriction of blood vessels. These symptoms are also known as menopausal symptoms. Women seek treatment for them most frequently during menopause. Female estrogen and progesterone levels begin to decrease around 40 years old. As women age, vasomotor symptoms may develop in females. Females might experience different symptoms due to hormonal fluctuations that affect temperature control and blood pressure. Hot flashes and night sweats are all signs of vasomotor symptoms. The best treatment for vasomotor symptoms is hormone therapy. The neuromodulators that estrogens have been known to be are potent, the neuromodulators of many neuronal circuits in the central nervous system. Temperature homeostasis is affected by multiple components, including estrogen levels. Specialists can also use this information to help them discover the causes of temperature regulation dysfunction and the mechanisms that regulate it. Vasomotor symptoms are primarily driven by the increasing prevalence of post-menopausal and menopausal symptoms.
A significant growth element is the creation of therapeutic options that target the brain's thermostat to reduce the frequency of vasomotor symptoms like hot flashes. Additionally, the growing acceptance of non-hormonal alternatives among patients with a history of breast cancer, such as selective serotonin reuptake inhibitors and selective serotonin-norepinephrine reuptake inhibitors, is promoting market expansion. The need for cognitive behavioural therapy, which can be used to treat vasomotor symptoms including sleep problems or low productivity in professional settings, is also contributing to the market's expansion. Nonpharmacologic treatment helps to modify dysfunctional emotions, behavior, and thoughts, which can help improve personal coping skills. Many governing bodies and non-governmental organizations (NGOs) are also supporting health education campaigns to combat stigmatization and silence around symptoms of menopause. This is also driving the use of medications and drugs to treat vasomotor symptoms. The vasomotor symptoms market will be driven by innovative methods to treat distressing vasomotor symptom.
These include the use of the lowest effective dose for the shortest time. The vasomotor symptoms market is expected to grow due to an increase in companies investing in clinical trials candidates and research and developing.
This market is expanding due to the increase in mergers and acquisitions between manufacturers and research organisations to provide effective medical care to patients and generate substantial revenues through their sales options. Vasomotor symptoms market growth is being accelerated by the increasing prevalence of these symptoms in people who are more sedentary and less active. Diverse public and private organisations are increasing their investment in new interventions and treatments to further influence the market. The vasomotor symptoms market is also growing due to a rise in healthcare spending, an increase in the demand for effective therapies and technological development.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Vasomotor Symptoms Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Vasomotor Symptoms Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.
• Eli Lilly and Company
• Emcure Pharmaceuticals Ltd
• Merck and Co
• Mithra Pharmaceuticals
• Novartis AG
• Novo Nordisk A/S
• Pfizer Inc
• Teva Pharmaceuticals
• TherapeuticsMD
• Procter and Gamble
(Note: The list of the major players will be updated with the latest market scenario and trends)
By Therapy Type
• Estrogen
• Progesterone
• Combination
• OTC Hormone
• Anti-Depressants
• Others
By End-user
• Hospitals
clinics
• Specilaty Centers
• Others
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Other Distribution Channels
By Region
• North America
Europe
• Asia-Pacific
• Latin America
• Middle East and Africa
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth
• To provide with an exhaustive analysis on the Vasomotor Symptoms Market By Therapy Type, By End-user, By Distribution Channel and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Vasomotor Symptoms Market Variables, Trends
    • Scope
        1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances
  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Vasomotor Symptoms Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Vasomotor Symptoms Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Vasomotor Symptoms Market, By Therapy Type Historical Analysis and Forecast 2022-2028 (USD Million)
    •   1. Estrogen
        2. Progesterone
        3. Combination
        4. OTC Hormone
        5. Anti-Depressants
        6. Others
  • 8.   Vasomotor Symptoms Market, By End-user Historical Analysis and Forecast 2022-2028 (USD Million)
    •   1. Hospitals
      clinics
        2. Specilaty Centers
        3. Others
  • 9.   Vasomotor Symptoms Market, By Distribution Channel Historical Analysis and Forecast 2022-2028 (USD Million)
    •   1. Hospital Pharmacies
        2. Retail Pharmacies
        3. Other Distribution Channels
  • 10.   North America Vasomotor Symptoms Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
           2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2022-2028
  • 11.   Latin America Vasomotor Symptoms Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2022-2028
  • 12.   Europe Vasomotor Symptoms Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         2.1. Germany
          2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2022-2028
  • 13.   Asia Pacific Vasomotor Symptoms Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028
  • 14.   Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2022-2028
  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Eli Lilly and Company
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Emcure Pharmaceuticals Ltd
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Merck and Co
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Mithra Pharmaceuticals
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Novartis AG
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Novo Nordisk A/S
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Pfizer Inc
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Teva Pharmaceuticals
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. TherapeuticsMD
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10.Procter and Gamble
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients